Evidence map›Paper›PMID 32006301›Full record

ReviewCurrent hematologic malignancy reports2020

Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.

Saurabh Zanwar, Jithma Prasad Abeykoon, Prashant Kapoor

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current hematologic malignancy reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Saurabh ZanwarDepartment of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Jithma Prasad AbeykoonDepartment of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Prashant KapoorDepartment of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. kapoor.prashant@mayo.edu.
Mayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewRecent advances the genomic profiling of patients with Waldenström macroglobulinemia (WM) have led to the identification of novel therapeutic targets in these patients. In this review, we cover the current standard of care and the recently evaluated novel approaches with high potential to be incorporated in the therapeutic armamentarium against WM. RECENT

findingsThe MYD88

Indexed as

Molecular Targeted TherapyAgammaglobulinaemia Tyrosine KinaseAnimalsGenetic Predisposition to DiseaseHumansMutationMyeloid Differentiation Factor 88Phosphoinositide-3 Kinase InhibitorsProteasome InhibitorsProtein Kinase InhibitorsProto-Oncogene Proteins c-bcl-2Receptors, CXCR4Signal TransductionWaldenstrom MacroglobulinemiaAgammaglobulinaemia Tyrosine KinaseBCL2 protein, humanBTK protein, humanCXCR4 protein, humanMYD88 protein, humanMyeloid Differentiation Factor 88Phosphoinositide-3 Kinase InhibitorsProteasome InhibitorsProtein Kinase InhibitorsProto-Oncogene Proteins c-bcl-2Receptors, CXCR4BTK inhibitorsCXCR4IgM lymphoplasmacytic lymphomaMYD88Non-Hodgkin lymphoma

Identifiers

PMID32006301
OpenAlexW3003906250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.